Shareholders Equity (Quarterly) Chart

View Shareholders Equity (Quarterly) for DMAC.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Shareholders Equity (Quarterly) Chart
Start Trial

Historical Shareholders Equity (Quarterly) Data

View and export this data back to 2007. Start Trial.
Date Value
June 30, 2026 38.34M
March 31, 2026 47.24M
December 31, 2025 56.11M
September 30, 2025 51.62M
June 30, 2025 27.17M
March 31, 2025 33.95M
December 31, 2024 40.72M
September 30, 2024 47.96M
June 30, 2024 53.42M
March 31, 2024 46.35M
December 31, 2023 51.06M
September 30, 2023 55.63M
June 30, 2023 59.74M
March 31, 2023 27.02M
December 31, 2022 31.83M
September 30, 2022 35.08M
June 30, 2022 37.72M
March 31, 2022 40.77M
December 31, 2021 44.02M
September 30, 2021 47.04M
June 30, 2021 20.32M
March 31, 2021 23.14M
December 31, 2020 26.01M
September 30, 2020 29.76M
June 30, 2020 11.27M
Date Value
March 31, 2020 13.32M
December 31, 2019 7.617M
September 30, 2019 9.70M
June 30, 2019 11.70M
March 31, 2019 13.91M
December 31, 2018
September 30, 2018 1.343M
June 30, 2018 1.465M
March 31, 2018 4.733M
December 31, 2017 0.792M
September 30, 2017 -0.0309M
June 30, 2017 0.7319M
March 31, 2017 0.0053M
December 31, 2016
September 30, 2016 1.619M
June 30, 2016 -1.036M
March 31, 2016 -1.017M
December 31, 2015 -1.228M
September 30, 2015 -1.147M
June 30, 2015 -0.9348M
March 31, 2015 -1.379M
December 31, 2014 -1.532M
September 30, 2014 -0.7099M
June 30, 2014 0.0862M
March 31, 2014 -0.3985M

Shareholders' Equity Definition

Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.

Read full definition.

Shareholders Equity (Quarterly) Range, Past 5 Years

View Shareholders Equity (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Shareholders Equity (Quarterly) Benchmarks

View Shareholders Equity (Quarterly) Benchmarks
Start Trial
ACADIA Pharmaceuticals, Inc. 1.307B
Alnylam Pharmaceuticals, Inc. 1.354B
Anika Therapeutics, Inc. 137.28M
Savara, Inc. 143.66M
Vericel Corp. 370.04M

Shareholders Equity (Quarterly) Related Metrics